Scancell Holdings plc (SCNLF PINK) stock market data APIs
$0.1266
0(0%)
as of March 13, 2025
Scancell Holdings plc Financial Data Overview
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer. It also develops Modi-1, a citrullinated peptides vaccine that is in phase I/II clinical trials for the treatment of solid tumors including triple negative breast, melanoma, ovarian, lung, and pancreatic cancers; and Modi-2, which targets homocitrullinated cancer antigens. In addition, the company focuses to develop SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.
Prev. Close
0.1266
Open
0.1266
High
0.1266
Low
0.1266
52 wk Range
0.1255-0.2335
Market Cap
131 M
Shares Outstanding
1 037 M
EPS
-0.0099
Beta
0.319
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Scancell Holdings plc data using free add-ons & libraries
Get Scancell Holdings plc Fundamental Data
Scancell Holdings plc Fundamental data includes:
- Net Revenue:
- EBITDA: -20 123 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-04-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Scancell Holdings plc News
New
Scancell Holdings "well-financed" and continuing to pursue deals
London, UK --News Direct-- Scancell Holdings PLC Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF)'s chief executive Professor Lindy Durrant speaks to Thomas Warner from Proactive to provide an update on t...
Investing in Scancell Holdings (LON:SCLP) three years ago would have delivered you a 146% gain
It hasn't been the best quarter for Scancell Holdings plc (LON:SCLP) shareholders, since the share price has fallen 21% in that time. But in three years the returns have been great. In three years the...
Even though Scancell Holdings (LON:SCLP) has lost UK£33m market cap in last 7 days, shareholders are still up 217% over 3 years
Scancell Holdings plc (LON:SCLP) shareholders might be concerned after seeing the share price drop 15% in the last week. In contrast, the return over three years has been impressive. The share price m...
Hedge funds investors own a significant stake of 44% in Scancell Holdings plc (LON:SCLP)
To get a sense of who is truly in control of Scancell Holdings plc (LON:SCLP), it is important to understand the ownership structure of the business. With 44% stake, hedge funds possess the maximum sh...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
